Mankind Pharma Share Price Target 2026, 2027, 2028, 2029, 2030

Mankind Pharma share price today

Mankind Pharma Ltd (NSE: MANKIND) is a pharma business with a market capitalisation of ₹1,00,589 Cr in Gale’s internal 6 August 2026 research snapshot. The stock was recorded at ₹2,456, against a 52-week range of ₹1,927 to ₹2,661. The live box above updates independently; every fundamental ratio below stays tied to the dated snapshot so market movement is never confused with a refreshed financial statement.

The central case is domestic distribution depth and brand-led optionality. A domestic prescription and OTC distribution machine with rural reach and consumer brands such as Manforce and Prega News. The internal figures show 13.5% ROCE, 13.1% ROE and 11.0% five-year profit growth. Those are attractive headline numbers, but the stock market pays for what comes next. This article therefore separates business quality, current momentum and valuation instead of treating them as one idea.

What the business actually earns money from

Mankind has built a broad domestic prescription business and nationally recognised consumer-health brands. Its distribution reaches beyond the largest cities, giving it access to markets where many premium-focused peers are thinner. Prescription brands, OTC products and acquired portfolios provide multiple growth routes.

The durable advantage is domestic distribution depth spanning prescription medicines and consumer-health brands. A moat should show up in numbers, not adjectives. Here the tests are return on capital, margin resilience, market-share behaviour and the amount of balance-sheet funding needed to grow. The snapshot’s 17.0% five-year average ROCE is more informative than a single strong year because it spans changes in demand and input costs.

Domestic reach reduces dependence on a single brand, but it does not eliminate price controls, doctor-coverage costs or consumer competition. Mankind must keep its core portfolio growing while integrating new assets and funding advertising. The franchise strengthens when distribution produces repeat demand; it weakens when growth requires ever more promotion or channel inventory.

The investment debate

The business has attractive reach and a 26% operating margin, but return ratios are not yet exceptional for the valuation. Investors must test whether acquisitions and expansion rebuild ROE rather than simply grow the balance sheet. Consumer brands create optionality, while regulated drug pricing and integration costs can reduce what ultimately reaches shareholders.

The historical growth split helps frame that debate. Sales compounded at 18.0% and profit at 11.0% over five years. Over three years those rates were 18.0% and 17.0%. Profit growth has accelerated versus the five-year record. That is not automatically bullish or bearish: acceleration can reflect a sustainable mix shift or a low base, while deceleration can be temporary or the first evidence that the old multiple is no longer deserved.

The stock sat about 7.7% below its 52-week high and 27.4% above its low in the snapshot. Distance from a high is not valuation. It is useful only when paired with earnings, balance-sheet and competitive evidence.

Prescription medicines and consumer health compound differently

Mankind’s prescription portfolio grows through doctor coverage, therapy selection, field-force productivity and brand retention. Consumer-health products depend more on retail availability, advertising and household recall. Both can benefit from the same distribution reach, but their customer-acquisition costs, pricing and repeat-purchase behaviour differ. A headline revenue number can therefore conceal a change in business quality.

The prescription engine deserves attention to chronic versus acute mix, volume growth and price-control exposure. Consumer brands should be judged on market share and contribution after advertising, not gross sales alone. A greater share of durable, repeat demand could support margin stability; promotion-led growth may look faster while consuming cash. Gale’s scenarios assume neither segment receives a free premium merely because it carries a recognised brand.

Distribution breadth is useful only if productivity follows

Mankind’s reach outside the largest cities is strategically valuable because it expands the addressable prescriber and pharmacy base. Yet adding representatives and stockists is an investment before it is an advantage. The operating proof is revenue per representative, prescription depth, inventory discipline and receivable quality. Channel stuffing can flatter shipments temporarily; end demand and cash collection expose it over time.

The 26% operating margin suggests the model has attractive economics, while 13.5% ROCE and 13.1% ROE show that the full capital base is not yet compounding at an exceptional rate. The gap between margin and return ratios matters. It may narrow as recent investments mature, but it could persist if acquisitions, working capital or underutilised assets absorb the operating profit. Better productivity, not reach alone, is the route to a higher-quality growth rate.

Acquisitions must rebuild returns, not just add brands

An acquired portfolio can add therapies, manufacturing assets and distribution synergies faster than internal development. It also brings integration cost, purchase consideration and the risk that expected cross-selling fails. Because Mankind’s current ROE sits below its five-year ROCE reference, shareholders should demand a visible path from larger balance sheet to higher per-share cash earnings.

Track net debt, goodwill, amortisation, working capital and operating cash flow alongside reported profit. A successful integration should sustain organic growth in the legacy business, lift the acquired portfolio and move returns upward as synergies arrive. If revenue grows but debt stays elevated and ROCE remains subdued, size has not translated into value. That distinction is why the model’s base growth rate remains below the strongest recent profit period.

Growth, margins and capital efficiency

Operating evidence	6 Aug 2026 snapshot	How to read it
Sales CAGR, 5 years	18.0%	Demand, pricing and consolidation together
Profit CAGR, 5 years	11.0%	Includes margin and financial leverage
Sales CAGR, 3 years	18.0%	More recent top-line momentum
Profit CAGR, 3 years	17.0%	More recent earnings momentum
Operating margin	26.0%	Business-model economics before interest and tax
ROCE / five-year ROCE	13.5% / 17.0%	Current return versus durability
ROE	13.1%	Return delivered on shareholder equity

The 26% operating margin is attractive, but Mankind’s 13.5% ROCE shows that not all invested capital is yet earning at the same quality. That gap is the central operating question. Returns should move toward the margin story as acquisitions integrate and field-force productivity improves. If margins remain high while ROCE stays subdued, balance-sheet growth—not just operating execution—is absorbing the value.

Sales have compounded at roughly 18% in both the three- and five-year windows, while profit growth recently caught up. That consistency supports a durable demand thesis, but the faster recent profit line may include mix or integration benefits that cannot repeat every year. Gale’s base case therefore uses 14% EPS growth, below the recent profit CAGR but above the longer record’s weakest interpretation.

Balance sheet, ownership and cash-flow questions

Debt to equity of 0.39 is manageable, but expansion should still be judged against operating cash flow. Promoter holding is 72.63%. The snapshot records zero promoter pledge, removing one common governance risk, though it does not replace scrutiny of related-party transactions and capital allocation.

Balance-sheet and ownership check	Snapshot
Debt to equity	0.39
Promoter holding	72.63%
Promoter pledge	0.00%
Book value per share	₹394.81
Dividend yield	0.04%

For Mankind, cash conversion depends on channel inventory, receivables, advertising outlay, acquisition payments and manufacturing capex. Compare operating cash flow with reported profit across several periods and separate one-time integration effects where disclosed. If working capital keeps expanding faster than domestic sales, reported brand momentum deserves a more cautious reading.

Dividend yield of 0.04% is not the main reason to own the stock; most of the expected return must come from earnings growth and valuation discipline. The payout should be viewed after necessary reinvestment, not in isolation.

The numbers

Metric	Internal research snapshot
Market capitalisation	₹1,00,589 Cr
Snapshot price	₹2,456
P/E · price/book	47.2 · 6.17
PEG · EV/EBITDA	2.76 · 25.6
ROE · ROCE	13.1% · 13.5%
Operating margin	26.0%
Debt/equity	0.39
EPS (TTM)	₹51.61
Book value per share	₹394.81
52-week range	₹1,927 – ₹2,661

Valuation: what today’s multiple already assumes

The snapshot P/E is 47.2 times, price/book 6.17 times, PEG 2.76, and EV/EBITDA 25.6 times. No one ratio settles the case. P/E connects price to shareholder earnings; EV/EBITDA helps compare operations before financing; price/book matters when the asset base is economically meaningful; PEG is only as reliable as the growth rate placed beneath it.

Quality alone is not a buying signal. At the recorded valuation, execution must justify a substantial premium; a wider margin of safety matters more than a confident story. The target framework compounds the recorded TTM EPS of ₹51.61 and applies different exit multiples. It does not assume that today’s multiple survives automatically. That distinction matters because a company can grow profit while its share price disappoints if the starting valuation was too optimistic.

Scenario	EPS growth assumption	Exit P/E	What must be true
Bear	8%	27×	Competitive or cyclical pressure slows growth and the premium contracts
Base	14%	37×	The core franchise executes without assuming a perfect cycle
Bull	20%	46×	Growth stays strong and the market continues to pay for quality

Mankind Pharma share price target 2026 to 2030

The bear, base and bull paths use the assumptions above for every year through 2030. They are scenario arithmetic, not a forecast of where the share must trade. The model uses one consistent diluted EPS base and rounds only the displayed outcomes. Dividends are not added to the price targets, so total shareholder return would differ from the table.

Scenario warning: earnings, capital structure and market multiples can all move outside these assumptions. Read the range as a sensitivity map, never as a promise or personalised recommendation.

The table is intentionally gated to a free signed-in account. That keeps the assumptions and target grid together, prevents a single number from being lifted out of context, and lets Gale show the member-only accumulation range separately from the public research.

What would change our mind

The thesis should be reviewed against measurable evidence, not daily price movement:

• Domestic prescription growth versus the Indian pharma market. A sustained adverse trend matters more than one noisy quarter.
• Consumer-health brand growth and advertising efficiency. A sustained adverse trend matters more than one noisy quarter.
• Acquisition integration, debt and return on capital. A sustained adverse trend matters more than one noisy quarter.
• ROE recovery from the current 13.1%. A sustained adverse trend matters more than one noisy quarter.

We would also revisit the model if equity dilution, a large acquisition or a material accounting change altered EPS comparability. Targets are not “set and forget”; the framework must be rebuilt when the business base changes.

Should you buy at the current price?

Mankind Pharma is a business to admire without automatically chasing the share. At this valuation, patience is an active decision: wait for either earnings to catch up or price to create a genuine margin of safety.

The signed-in panel shows Gale’s current rating, while paid members can see the accumulation range. Neither replaces position sizing or personal suitability. An investor already heavily exposed to pharma faces a different decision from someone building a diversified portfolio.

FAQ

What is the Mankind Pharma share price target for 2030?

Gale publishes bear, base and bull outcomes for 2026–2030 in the signed-in table on this page. Each number comes from the stated EPS growth and exit P/E assumptions; there is no single assured target.

Is Mankind Pharma overvalued?

At 47.2 times earnings and 25.6 times EV/EBITDA in the snapshot, the shares require continued earnings delivery. Valuation becomes attractive only when the return implied by conservative assumptions compensates for the business risks.

What is Mankind Pharma’s main advantage?

The core advantage is domestic distribution depth spanning prescription medicines and consumer-health brands. The evidence to follow is whether that advantage continues to produce stable market share, margins and returns on capital.

What is the biggest risk to the target model?

ROE has slipped after the listing period; acquisition integration, price controls and the premium multiple are the key tests. A lower growth rate and a lower multiple can occur together, which is why the bear path changes both variables.

Does Mankind Pharma pay a dividend?

The internal snapshot records a 0.04% dividend yield. It is secondary to earnings growth, and future payouts remain subject to board decisions and cash needs.

When are Mankind Pharma’s next results?

Use Gale’s results calendar for the announced date and check the exchange filing before relying on an estimate.

Related research

• Sun Pharma share price target
• Glenmark Pharma share price target
• Torrent Pharma share price target

Sources: Screener.in company financials, captured in Gale’s approved internal research snapshot on 6 August 2026; company results, annual reports and exchange filings linked from that page. Live market price is supplied separately by Yahoo Finance and is indicative.

---

This article is research and education, not personalised investment advice. We are not SEBI-registered advisers. Price targets are scenario arithmetic, not promises. Do your own research and consult a registered adviser before acting.